The A-share innovative drug sector weakened after a correction, with Haiwang Bio falling more than 9%, Guang Sheng Tang falling more than 6%, and Shuanglu Pharmaceutical and 3SBio following suit.
2026-04-07
The A-share innovative drug sector weakened after a correction, with Haiwang Bio falling more than 9%, Guang Sheng Tang falling more than 6%, and Shuanglu Pharmaceutical and 3SBio following suit.